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Dear Editor,
Treatment options for newly diagnosed multiple mye-
loma (NDMM) commonly include triplet regimens using
the ﬁrst-in-class proteasome inhibitor (PI) bortezomib, a
corticosteroid, and an alkylator or immunomodulator1,2.
Patients ultimately relapse with these regimens, and
bortezomib is associated with peripheral neuropathy
(PN)3. Additional effective, well-tolerated, and convenient
frontline treatment options are needed.
Carﬁlzomib is an intravenously administered, second-
generation, irreversible tetrapeptide PI approved for
relapsed or refractory multiple myeloma (RRMM)4. In
frontline studies, carﬁlzomib treatment resulted in hiqh-
quality responses with low PN rates5–8, demonstrating
therapeutic potential of second-generation, irreversible
PIs in this setting.
Oprozomib, a tripeptide analog of carﬁlzomib, is an
orally bioavailable PI9. Oprozomib has shown antitumor
activity comparable with carﬁlzomib in preclinical mod-
els9. In RRMM patients, oprozomib demonstrated pro-
mising efﬁcacy when used as a single-agent or in
combination therapy10–12. As continuous/extended ther-
apy has become increasingly important in NDMM, there
is a need for treatments with convenient dosing, such as
all-oral regimens. Oprozomib is expected to be a con-
venient treatment option, especially in all-oral regimens.
We conducted two phase 1b/2 studies evaluating three
oprozomib-based regimens for NDMM: the
OPZ003 study evaluated oprozomib-dexamethasone with
lenalidomide or cyclophosphamide (ORd or OCyd,
respectively); the OPZ006 study evaluated oprozomib-
melphalan-prednisone (OMP).
OPZ003 (NCT01881789) and OPZ006 (NCT02072863)
were multicenter, open-label, phase 1b/2 studies. Adult,
transplant-ineligible NDMM patients were eligible. The
primary objective of the phase 1b portions was to deter-
mine oprozomib’s maximum tolerated dose (MTD) using
a standard 3+ 3 dose escalation schema. Efﬁcacy was a
primary objective of the phase 2 portions. Disease
response was assessed by investigators according to
International Myeloma Working Group – Uniform
Response Criteria. Duration of response (DOR) was
deﬁned as time from achievement of a partial response
(PR) or better to conﬁrmed disease progression or death
due to any cause. Progression-free survival (PFS) was
deﬁned as time from treatment initiation to disease pro-
gression or death due to any cause. Both protocols were
approved by institutional review boards and patients
provided written informed consent.
In OPZ003, ORd patients received oprozomib orally on
days 1 through 5 and days 15 through 19 (5/14 schedule)
or on days 1, 2, 8, 9, 15, 16, 22, and 23 (2/7 schedule) of
every 28-day cycle. OCyd patients received the 2/7 sche-
dule only (Fig. S1). The starting oprozomib dose in
OPZ003 was 210 mg. ORd patients received oral lenali-
domide 25 mg on days 1–21. OCyd patients received oral
cyclophosphamide 300mg/m2 on days 1, 8, and 15.
Dexamethasone 20mg was given on the 2/7 schedule.
Treatment was administered until disease progression,
unacceptable toxicity, or for 24 (ORd) or 8 (OCyd) cycles,
whichever occurred ﬁrst. Concomitant medications
(including anti-diarrheals/anti-emetics) are described in
the supplement.
In OPZ006, patients received oprozomib orally on days
1–5, days 15–19, and days 29–33 with melphalan 9mg/
m2 and prednisone 60mg/m2 on days 1–4 of a 42-day
cycle. The starting oprozomib dose was 180mg. OMP was
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Table 1 Summary of the most common treatment-emergent adverse events
ORd OCyd OMP
n (%) 5/14 Schedule,
150–210mg OPZ N= 13
2/7 Schedule, 210 or
240mg OPZ N= 5
2/7 Schedule, 210mg OPZ
N= 3
2/7 Schedule, 180mg OPZ
N= 7
Any grade Grade 3 or
greater
Any grade Grade 3 or
greater
Any grade Grade 3 or
greater
Any grade Grade 3 or
greater
Nausea 11 (84.6) 0 5 (100.0) 0 2 (66.7) 0 5 (71.4) 1 (14.3)
Cough 2 (15.4) 0 5 (100.0) 0 1 (33.3) 0 0 0
Diarrhea 11 (84.6) 2 (15.4) 4 (80.0) 0 2 (66.7) 0 6 (85.7) 1 (14.3)
Fatigue 7 (53.8) 1 (7.7) 4 (80.0) 1 (20.0) 1 (33.3) 1 (33.3) 2 (28.6) 0
Vomiting 7 (53.8) 0 4 (80.0) 0 0 0 4 (57.1) 1 (14.3)
Dizziness 7 (53.8) 1 (7.7) 3 (60.0) 0 1 (33.3) 0 1 (14.3) 1 (14.3)
Constipation 6 (46.2) 0 3 (60.0) 0 0 0 3 (42.9) 0
Decreased appetite 3 (23.1) 0 3 (60.0) 0 1 (33.3) 0 1 (14.3) 0
Dysgeusia 3 (23.1) 0 3 (60.0) 0 1 (33.3) 0 1 (14.3) 0
Headache 2 (15.4) 0 0 0 2 (66.7) 0 1 (14.3) 0
Dyspepsia 1 (7.7) 0 3 (60.0) 0 1 (33.3) 0 0 0
Thrombocytopenia 4 (30.8) 2 (15.4) 0 0 0 0 2 (28.6) 0
Hypokalemia 4 (30.8) 0 0 0 0 0 0 0
Upper respiratory tract
infection
2 (15.4) 0 0 0 2 (66.7) 0 0 0
Abdominal distension 2 (15.4) 1 (7.7) 2 (40.0) 0 2 (66.7) 0 1 (14.3) 0
Muscle spasms 2 (15.4) 0 2 (40.0) 0 2 (66.7) 0 1 (14.3) 0
Vision blurred 1 (7.7) 0 2 (40.0) 0 2 (66.7) 0 0 0
Hypotension 4 (30.8) 2 (15.4) 1 (20.0) 0 0 0 0 0
Asthenia 2 (15.4) 0 1 (20.0) 0 1 (33.3) 0 2 (28.6) 0
Insomnia 2 (15.4) 0 3 (60.0) 0 0 0 0 0
Hypocalcemia 1 (7.7) 0 3 (60.0) 1 (20.0) 0 0 0 0
Tremor 1 (7.7) 0 3 (60.0) 0 0 0 0 0
Dysphonia 0 0 3 (60.0) 0 0 0 0 0
AST increased 1 (7.7) 0 1 (20.0) 0 0 0 2 (28.6) 1 (14.3)
Dyspnea exertional 1 (7.7) 0 1 (20.0) 0 0 0 2 (28.6) 1 (14.3)
Tachycardia 0 0 1 (20.0) 0 2 (66.7) 0 0 0
Edema 1 (7.7) 0 0 0 1 (33.3) 0 2 (28.6) 0
ALT increased 1 (7.7) 1 (7.7) 0 0 1 (33.3) 0 2 (28.6) 2 (28.6)
Hypertension 0 0 2 (40.0) 0 0 0 2 (28.6) 1 (14.3)
Fluid retention 0 0 0 0 0 0 2 (28.6) 0
Abdominal pain upper 1 (7.7) 0 0 0 0 0 3 (42.9) 0
The most common any-grade adverse events listed are those that occurred in ≥4 patients in the ORd, 5/14 cohort; or ≥3 patients in the ORd, 2/7 cohort; or ≥2 patients
in the OCyd cohort; or ≥2 patients in the OMP cohort
AE adverse event, ALT alanine aminotransferase, AST aspartate aminotransferase, OCyd oprozomib, cyclophosphamide, and dexamethasone; OMP oprozomib,
melphalan, and prednisone; OPZ oprozomib, ORd oprozomib, lenalidomide, and dexamethasone
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administered until disease progression, unacceptable
toxicity, or nine cycles, whichever occurred ﬁrst.
Twenty-two patients were enrolled in OPZ003, and 21
treated. Median age was 67 years (range, 54–79) (Table
S1). At data cut-off, seven OPZ006 patients were treated.
Median age was 71 years (range 66–84). Eighteen OPZ003
patients and ﬁve OPZ006 patients discontinued treatment
(reasons given in Table S2).
The ORd arm of the OPZ003 study started with the 5/
14 schedule, and the ﬁrst dosing level tested was 210mg
(n= 3). This schedule required two preplanned dose de-
escalations to 180mg and then subsequently to 150mg
due to DLTs (Table S3). Because of these results with the
5/14 schedule, the protocol was amended and the ORd
regimen enrolled two cohorts with the 2/7 schedule: a
starting cohort at 210mg and an escalation to 240mg
where one DLT occurred (Table S3). Comparatively, the
OCyd arm started with the 2/7 schedule with a dose of
210mg. A program evaluation identiﬁed that the safety
proﬁle and pharmacokinetic (PK) characteristics of the
formulation used in all oprozomib studies required fur-
ther optimization and thus enrollment in OPZ003 was
halted during dose-escalation. The MTD of oprozomib
for ORd or OCyd could not be established because there
were not enough data for MTD determination. Only
OPZ006 patients enrolled in the ﬁrst dosing cohort
(180 mg; n= 7) were treated before the study was termi-
nated based on sponsor decision to not pursue the OMP
combination; thus the MTD of oprozomib for OMP could
also not be established.
In OPZ003, mean duration of oprozomib administra-
tion was 16.2 weeks (range, 0.6‒97.7) on the 5/14 schedule
in the ORd arm, 36.6 weeks (range, 0.3‒72.3) on the 2/
7 schedule in the ORd arm, and 42.0 weeks (range, 15.3‒
64.3) on the 2/7 schedule in the OCyd arm. All patients
reported a treatment-emergent adverse event (TEAE;
Table 1). Grade ≥ 3 TEAEs were reported for 12 patients
(92.3%) on the 5/14 schedule in the ORd arm, ﬁve patients
(100%) on the 2/7 schedule in the ORd arm, and two
patients (66.7%) on the 2/7 schedule in the OCyd arm.
AE-related discontinuations occurred in four patients
(30.8%) on the 5/14 schedule in the ORd arm and two
patients (40.0%) on the 2/7 schedule in the ORd arm
(supplement). No patient on the 2/7 schedule in the OCyd
arm discontinued due to AEs.
In OPZ006, the mean duration of oprozomib exposure
was 22.3 weeks (range, 1–53). TEAEs were reported for all
OPZ006 patients (Table 1). Grade ≥ 3 TEAEs were
reported in ﬁve patients (71.4%). Three patients (42.9%)
had a TEAE that led to oprozomib discontinuation
(supplement). Gastrointestinal AEs were among the most
common TEAEs in OPZ003 and OPZ006. In the ORd 5/
14 cohort, diarrhea, nausea, and vomiting rates were 84.6,
84.6, and 53.8%.
Among 21 treated OPZ003 patients (ORd 5/14, n= 13;
ORd 2/7, n= 5; OCyd, n= 3), 15 achieved ≥PR (overall
response rate [ORR], 71.4%) (Table 2); 38% achieved
≥very good PR. Two patients achieved a complete
response (CR) and one a stringent CR. All achieved
≥stable disease. The time to response ranged from 22 to
98 days. ORR was 66.7% in ORd-treated patients (5/14,
61.5%; 2/7, 80.0%) and 100.0% in OCyd-treated patients.
ORR was 100.0% for ORd- or OCyd-treated patients
receiving ≥2 cycles. None of the patients experienced
disease progression or death within the follow-up period;
median (95% CI) follow-up times were 3.7 (0.7–4.4)
Table 2 Treatment responses
ORd OCyd OMP
5/14 Schedule,
150–210mg OPZ N= 13
2/7 Schedule, 210 or





Best overall response, n (%)
Stringent complete response 0 1 (20.0) 0 0
Complete response 2 (15.4) 0 0 1 (14.3)
Very good partial response 2 (15.4) 2 (40.0) 1 (33.3) 0
Partial response 4 (30.8) 1 (20.0) 2 (66.7) 2 (28.6)
Stable disease 1 (7.7) 0 0 3 (42.9)
Not evaluable 2 (15.4) 0 0 0
Missing or unknown 2 (15.4) 1 (20.0) 0 1 (14.3)
Overall response rate, % 61.5 80.0 100.0 42.9
OCyd oprozomib, cyclophosphamide, and dexamethasone; OMP oprozomib, melphalan, and prednisone; OPZ oprozomib; ORd oprozomib, lenalidomide, and
dexamethasone
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months (ORd, 5/14 schedule), 11.4 (3.6–16.8) months
(ORd, 2/7 schedule), and 11.2 (3.8–15.0) months (OCyd,
2/7 schedule).
Among seven OMP-treated patients in OPZ006, ORR
was 42.9% (Table 2). One patient achieved CR and two
achieved PR.
In conclusion, although antimyeloma activity (including
CRs) was demonstrated in NDMM patients, gastro-
intestinal toxicities and variable PK were concerns with
the oprozomib formulation used in this study. Dose-
escalation above the starting dose occurred on the 2/7 but
not 5/14 schedule, possibly because this schedule was
more tolerable. The 2/7 schedule is being taken forward in
a phase 1b, dose-exploration study (NCT02939183) in
RRMM that is evaluating the two new oprozomib for-
mulations to determine whether a lower maximum
plasma concentration could improve gastrointestinal tol-
erability and whether a faster dissolution could limit
pharmacokinetic variability.
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